The U.S. Food and Drug Administration announced on Tuesday, July 2nd that it has approved Kisunla™ (donanemab-azbt) for Early Symptomatic Alzheimer’s and Mild Cognitive Impairment.
According to manufacturer Eli Lilly, “once-monthly [Kisunla] infusions of 30 minutes reduced amyloid plaques on average by 84% compared to the start of the study and slowed cognitive and functional decline by up to 35% compared to placebo at 18 months in its pivotal Phase 3 study. [Kisula] reduced participants’ risk of progressing to the next clinical stage of disease by up to 39%.”
The FDA’s approval emphasizes the importance of early diagnosis, showing the most significant improvements were found in early-stage patients. “It is our responsibility as caregivers and healthcare providers to advocate for the benefits of an early diagnosis as well as encourage open conversations about the signs and symptoms of Alzheimer’s without stigma” shared Rachel Takacs, Certified Dementia Practitioner and Director of Navigation at Waveny LifeCare Network.
Learn more about eligibility and treatment details in the official release from Eli Lilly, https://investor.lilly.com/news-releases/news-release-details/lillys-kisunlatm-donanemab-azbt-approved-fda-treatment-early.
Waveny remains committed to advancing Alzheimer’s research and accessible treatments. This new milestone encourages our belief that we are getting closer to finding a cure for Alzheimer’s disease.
